Advertisement
U.S. markets closed
S&P Futures
6,007.50 +1.00 (+0.02%) Dow Futures
44,833.00 +7.00 (+0.02%) Nasdaq Futures
20,899.25 +19.00 (+0.09%) Russell 2000 Futures
2,441.20 -9.80 (-0.40%) Crude Oil
69.20 +0.26 (+0.38%) Gold
2,630.50 +12.00 (+0.46%)
At close: 04:00PM EST
After hours:
| Previous Close | 48.28 |
| Open | 48.74 |
| Bid | 48.35 x 800 |
| Ask | 48.41 x 300 |
| Day's Range | 48.25 - 48.78 |
| 52 Week Range | 45.22 - 58.97 |
| Volume | |
| Avg. Volume | 1,923,417 |
| Market Cap | 121.222B |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | 25.72 |
| EPS (TTM) | 1.88 |
| Earnings Date | Jan 30, 2025 |
| Forward Dividend & Yield | 2.04 (4.22%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | 63.49 |
- Zacks Small Cap Research
MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement…
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Monetary Damages Due from Sanofi/Novartis Litigation Settlement On November 11, 2024, MediciNova, Inc. (NASDAQ:MNOV) announced a settlement in the patent litigation brought by Genzyme Corporation, a subsidiary of Sanofi, against Novartis. The litigation included a claim for infringement of U.S. Patent No.
Pharmaceutical TechnologyTrump’s presidency return: boom or bust for biopharmaceutical deal activity?
It remains to be seen how Trump's 'America First' foreign policies will impact the ability of ex-US companies in the sector.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.